Brokerages expect that Eagle Pharmaceuticals Inc (NASDAQ:EGRX) will report earnings per share (EPS) of $0.26 for the current fiscal quarter, Zacks Investment Research reports. Two analysts have made estimates for Eagle Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at $0.16 and the highest estimate coming in at $0.36. Eagle Pharmaceuticals also reported earnings per share of $0.26 in the same quarter last year. The business is expected to report its next quarterly earnings results on Tuesday, November 10th.
According to Zacks, analysts expect that Eagle Pharmaceuticals will report full year earnings of $2.21 per share for the current fiscal year, with EPS estimates ranging from $2.00 to $2.44. For the next year, analysts anticipate that the business will post earnings of $2.52 per share, with EPS estimates ranging from $1.90 to $3.05. Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research firms that that provide coverage for Eagle Pharmaceuticals.
Eagle Pharmaceuticals (NASDAQ:EGRX) last released its earnings results on Monday, August 10th. The specialty pharmaceutical company reported $0.57 EPS for the quarter, topping the consensus estimate of $0.24 by $0.33. The firm had revenue of $41.94 million for the quarter, compared to the consensus estimate of $37.46 million. Eagle Pharmaceuticals had a negative net margin of 2.54% and a positive return on equity of 4.11%.
Several brokerages have recently issued reports on EGRX. Zacks Investment Research raised Eagle Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Tuesday, September 15th. BidaskClub raised Eagle Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday. Finally, ValuEngine downgraded Eagle Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday. Four analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. Eagle Pharmaceuticals currently has an average rating of “Hold” and an average price target of $53.67.
EGRX stock traded down $1.35 during mid-day trading on Monday, hitting $41.72. The company had a trading volume of 166,081 shares, compared to its average volume of 176,694. The company has a 50-day moving average price of $40.01 and a 200 day moving average price of $46.14. Eagle Pharmaceuticals has a 12-month low of $33.80 and a 12-month high of $64.94. The company has a market capitalization of $567.68 million, a price-to-earnings ratio of -126.42 and a beta of 0.77. The company has a quick ratio of 3.97, a current ratio of 4.16 and a debt-to-equity ratio of 0.16.
Large investors have recently made changes to their positions in the business. Tang Capital Management LLC bought a new stake in shares of Eagle Pharmaceuticals during the 1st quarter worth approximately $11,758,000. Schroder Investment Management Group boosted its stake in shares of Eagle Pharmaceuticals by 412.5% during the first quarter. Schroder Investment Management Group now owns 245,497 shares of the specialty pharmaceutical company’s stock valued at $11,619,000 after purchasing an additional 197,592 shares during the period. Prudential Financial Inc. boosted its stake in shares of Eagle Pharmaceuticals by 82.2% during the second quarter. Prudential Financial Inc. now owns 213,045 shares of the specialty pharmaceutical company’s stock valued at $10,222,000 after purchasing an additional 96,125 shares during the period. Aviva PLC bought a new position in shares of Eagle Pharmaceuticals in the first quarter worth about $3,884,000. Finally, Park West Asset Management LLC increased its stake in Eagle Pharmaceuticals by 5.4% in the 1st quarter. Park West Asset Management LLC now owns 1,234,856 shares of the specialty pharmaceutical company’s stock worth $56,803,000 after buying an additional 62,976 shares during the period. Institutional investors and hedge funds own 95.38% of the company’s stock.
Eagle Pharmaceuticals Company Profile
Eagle Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company offers Argatroban, an anti-coagulant thrombin inhibitor for heparin-induced thrombocytopenia; Ryanodex for malignant hyperthermia; Bendeka for chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin's lymphoma (NHL); and Belrapzo, a chemotherapeutic agent for CLL and Indolent NHL.
Read More: Current Ratio
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Eagle Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.